Quartz Partners LLC Acquires New Shares in ANI Pharmaceuticals, Inc. $ANIP

Quartz Partners LLC bought a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 2nd quarter, HoldingsChannel reports. The firm bought 19,424 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,608,000.

A number of other institutional investors and hedge funds have also modified their holdings of ANIP. Maryland State Retirement & Pension System raised its stake in shares of ANI Pharmaceuticals by 5.4% in the fourth quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after purchasing an additional 134 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 143 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its position in shares of ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after buying an additional 198 shares during the last quarter. Oregon Public Employees Retirement Fund increased its holdings in ANI Pharmaceuticals by 5.1% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after buying an additional 200 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec increased its holdings in ANI Pharmaceuticals by 0.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 39,391 shares of the specialty pharmaceutical company’s stock worth $3,110,000 after buying an additional 221 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, Director Thomas Haughey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $80.88, for a total value of $161,760.00. Following the transaction, the director owned 38,878 shares of the company’s stock, valued at approximately $3,144,452.64. This trade represents a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Stephen P. Carey sold 3,313 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the completion of the transaction, the chief financial officer directly owned 177,543 shares in the company, valued at approximately $15,268,698. The trade was a 1.83% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,987 shares of company stock worth $1,546,405 over the last quarter. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Up 1.5%

ANI Pharmaceuticals stock opened at $78.02 on Thursday. The stock has a market cap of $1.79 billion, a PE ratio of 16.81 and a beta of 0.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals, Inc. has a one year low of $70.15 and a one year high of $99.50. The stock has a fifty day moving average of $80.57 and a 200 day moving average of $78.94.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business’s revenue for the quarter was up 25.8% on a year-over-year basis. During the same period last year, the firm posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Analyst Ratings Changes

ANIP has been the subject of a number of recent analyst reports. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Canaccord Genuity Group decreased their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Finally, Guggenheim dropped their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.